Concord Biotech Ltd. (CONCORDBIO) AI Stock Analysis

• Market Cap: ₹138.18B
• Dividend Yield: 0.8%
• Average Volume (3M): 12.81K
• Price to Earnings (P/E): 42.7
• Beta (1Y): 1.06
• Revenue Growth: 3.63%
• EPS Growth: -1.21%
• Country: IN
• Employees: 1,377
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 6.10
• Shares Outstanding: 104,616,200
• 10 Day Avg. Volume: 31,605
• 30 Day Avg. Volume: 12,808
• PEG Ratio: 2.27
• Price to Book (P/B): 9.60
• Price to Sales (P/S): 14.50
• P/FCF Ratio: 127.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: ₹1,539.00 ▲(14.97% Upside)

Concord Biotech Ltd. has a strong financial foundation with excellent revenue and profit growth, supported by a robust balance sheet. However, the technical indicators suggest bearish momentum, and the valuation appears high, which could limit upside potential. The lack of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Strong Financial Performance

The company's robust revenue and profit growth indicate a solid business model and effective market strategies, ensuring long-term financial health.

Balance Sheet Strength

A strong balance sheet with low leverage enhances financial stability, allowing for strategic investments and resilience against economic downturns.

Cash Flow Management

Consistently positive operating cash flow reflects efficient operations and the ability to fund growth initiatives internally, supporting long-term sustainability.

Negative Factors

Inconsistent Free Cash Flow Growth

Inconsistent free cash flow growth can hinder the company's ability to invest in new projects or technologies, impacting future growth potential.

Decreasing Gross Profit Margin

A decreasing gross profit margin suggests rising costs or pricing pressures, which could erode profitability if not managed effectively.

Lack of Earnings Call Data

The absence of earnings call data limits transparency and insights into management's strategic direction, potentially affecting investor confidence.

Concord Biotech Ltd. Business Overview & Revenue Model

Company Description

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

How the Company Makes Money

Concord Biotech generates revenue primarily through the sale of its biopharmaceutical products, including biosimilars and APIs. The company engages in both direct sales and partnerships with other pharmaceutical companies, which may involve licensing agreements and co-development arrangements. Significant revenue streams include the commercialization of biosimilars in various markets, where they compete with original biologics, as well as supplying APIs to other pharmaceutical manufacturers. Additionally, strategic collaborations with research institutions and industry partners for the development of new products contribute to its earnings, enhancing its market presence and expanding its product portfolio.

Concord Biotech Ltd. Financial Statement Overview

Summary

Concord Biotech Ltd. exhibits strong financial performance with robust revenue and profit growth. The balance sheet is particularly strong, with low leverage and high equity, providing financial security. Cash flow management is generally effective, though variability in free cash flow growth suggests a need for careful future capital planning.

Income Statement

Concord Biotech Ltd. has demonstrated strong revenue growth over the years, with a notable increase from 2020 to 2025. Gross profit margin and net profit margin are robust, reflecting efficient cost management and operational success. The EBIT and EBITDA margins indicate solid profitability, with consistent growth. However, the gross profit margin has slightly decreased, signaling potential cost pressures that need monitoring.

Balance Sheet

The balance sheet is strong, with a low debt-to-equity ratio, indicating minimal financial leverage and risk. The equity ratio is high, showing significant equity financing. Return on equity is commendable, highlighting effective use of shareholder funds. Overall, the company shows financial stability and prudent financial management.

Cash Flow

Operating cash flow is consistently positive and growing, underscoring effective cash management. Free cash flow also shows positive trends, although growth has fluctuated across the years. The operating cash flow to net income ratio is favorable, indicating good cash conversion from profits. However, the free cash flow growth rate has been inconsistent, presenting potential challenges in sustaining capital investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	11.88B	12.00B	10.17B	8.53B	7.13B	6.17B
Gross Profit	7.87B	7.68B	6.67B	6.61B	5.41B	5.00B
EBITDA	4.89B	5.13B	4.39B	3.53B	2.78B	3.29B
Net Income	3.56B	3.72B	3.08B	2.40B	1.75B	2.35B
Balance Sheet
Total Assets	0.00	20.34B	17.01B	15.14B	13.13B	11.83B
Cash, Cash Equivalents and Short-Term Investments	3.18B	3.18B	2.86B	1.81B	1.62B	2.01B
Total Debt	0.00	29.69M	97.38M	315.47M	624.93M	892.83M
Total Liabilities	-18.13B	2.22B	1.74B	2.24B	2.10B	1.83B
Stockholders Equity	18.13B	18.13B	15.27B	12.90B	11.03B	9.99B
Cash Flow
Free Cash Flow	0.00	1.36B	1.80B	1.01B	519.70M	-373.59M
Operating Cash Flow	0.00	2.47B	2.65B	2.46B	2.07B	1.67B
Investing Cash Flow	0.00	-1.63B	-1.55B	-1.58B	-1.12B	-1.95B
Financing Cash Flow	0.00	-986.67M	-992.15M	-852.19M	-1.00B	311.24M

Concord Biotech Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1338.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CONCORDBIO, the sentiment is Neutral. The current price of 1338.6 is below the 20-day moving average (MA) of 1348.56, below the 50-day MA of 1401.21, and below the 200-day MA of 1613.34, indicating a neutral trend. The MACD of -17.93 indicates Negative momentum. The RSI at 50.50 is Neutral, neither overbought nor oversold. The STOCH value of 57.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:CONCORDBIO.

Concord Biotech Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYNGENE	71 Outperform	₹252.74B	53.77	―	0.19%	8.57%	-2.93%
BIOCON	63 Neutral	₹506.62B	95.62	―	0.12%	10.62%	-66.88%
JUBLINGREA	63 Neutral	₹109.29B	37.58	―	0.74%	3.80%	64.94%
CONCORDBIO	61 Neutral	₹138.18B	42.65	―	0.80%	3.63%	-1.21%
BLUEJET	61 Neutral	₹86.88B	24.65	―	0.22%	63.34%	109.89%
PPLPHARMA	55 Neutral	₹224.11B	-925.86	―	0.08%	2.66%	-153.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Concord Biotech Ltd. Corporate Events

Concord Biotech Updates Key Managerial Authorisations for Market Disclosures

Concord Biotech Limited has revised the list of key managerial personnel (KMPs) authorized to determine the materiality of events and information and to make corresponding disclosures to stock exchanges under SEBI’s Listing Obligations and Disclosure Requirements. The updated authorized KMPs now include Chairman and Managing Director Sudhir Vaid, Joint Managing Director and CEO Ankur Vaid, Chief Financial Officer Raviraj Karia, and Company Secretary and Compliance Officer Hina Patel, a move that formalizes the company’s internal governance framework for market disclosures and reinforces its compliance processes for timely and accurate communication with investors and regulators.